History & Milestones

CombinatoRx founded by Alexis Borisy and his co-founders (Brent R. Stockwell Ph.D., Michael A. Foley Ph.D., Curtis T. Keith Ph.D. and Jacob D. Goldfield) based on the then theoretical idea that selective action through synergy between two drugs could create fundamentally better medicines

Invented and built working prototype of combination High Throughput Screening (cHTS™) drug discovery technology

Synergistic combination High Throughput Screening (cHTS™) technology was tested, refined and proven to work in a variety of model systems

Established first wave of a broad pipeline with seven drug candidates in phase 2 clinical trials

Collaborations

• Collaboration with Angiotech Pharmaceuticals, Inc. to discover and develop compounds for use in medical devices and other interventional medicine products
• Formed CombinatoRx Singapore, and in collaboration with Bio*One, to discover and develop novel treatments of infectious diseases
• Collaborated with Cure Huntington's Disease Initiative (CHDI) to discover and develop drug candidates that may prevent or slow progression of Huntington's disease

Positive Human Clinical Trials

• CRx-102 - Positive clinical results (hand osteoarthritis and rheumatoid arthritis)
• CRx-170 - Positive clinical results (asthma)

Collaborations

• Joined forces with Cystic Fibrosis Foundation Therapeutics (CFFT) to develop novel cystic fibrosis therapeutics
• Collaborated with Fovea Pharmaceuticals SA to develop synergistic combination formulations to treat ophthalmic diseases

Collaborations

• Extension of the collaboration with Angiotech Pharmaceuticals, Inc. for an additional 2 1/2 years triggering a $7 million payment to CombinatoRx based upon the successful advancement of a number of product candidates in relevant preclinical models.